Search clinical trials for: complete cytogenetic response

Total 15875 results

American University of Beirut Medical Center

Recruiting

Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

Lebanon
M.D. Anderson Cancer Center
Ariad Pharmaceuticals

Terminated

Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)

Leukemia

United States
Cancer Trials Ireland

Terminated

CharactHer. ICORG 12-09, V3

HER2-positive Breast Cancer | TNM Stage II-IV Breast Cancer

Ireland, Italy
Fusion Pharma LLC
Data Matrix Solutions; OCT Rus, LLC; Skolkovo Innovation Center

Unknown

Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene

Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Chronic Myeloid Leukemia

Russian Federation
Gesellschaft fur Medizinische Innovation - Hamatologie...
Crolll Gmbh

Completed

Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation (Crescendo)

Chronic Myelogenous Leukemia (CML)

Germany
Università degli Studi di Brescia

Completed

Follow-up of Ph+ Chronic Myleoid Leukemia Patients in Complete Cytogenetic Response With Interferon Based Therapy

Chronic Myeloid Leukemia

Italy
Novartis Pharmaceuticals

Completed

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

Chronic Myelogenous Leukemia

Canada
University of Michigan Rogel Cancer Center

Terminated

Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha

Chronic Myeloid Leukemia

United States
Università degli Studi di Brescia

Completed

Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy (INTERIM0407)

Chronic Myeloid Leukemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy

Chronic Myeloid Leukemia

Italy
Bristol-Myers Squibb

Terminated

A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

Leukemia

United States
Sheba Medical Center

Unknown

Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

Leukemia, Myeloid, Philadelphia-Positive

Israel
Peking University People's Hospital
Akeso Pharmaceuticals, Inc.

Not yet recruiting

Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma
Changhai Hospital
Shanghai 10th People's Hospital; Ruijin Hospital; Shanghai Ninth People's Hospital... and other collaborators

Not yet recruiting

Real-World Clinical Study on the Efficacy of Vibrating Capsule (Vibrabot Capsule) for Chronic Functional Constipation (RWS-VC)

Clinical Study | Chronic Functional Constipation

China
Ferring Pharmaceuticals

Not yet recruiting

A Phase 4, Multi-center, Open Label Trial to Evaluate Efficacy of Retreatment With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose (ABLE-42)

Bladder Cancer | CIS | Ta/T1
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer

Predictive Cancer Model | Pathologic Complete Response

China
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Non Small Cell Lung Cancer

United States, Israel, Taiwan, Korea, Republic of, Switzerland
Hospices Civils de Lyon

Not yet recruiting

Contrast-enhanced Spectral Mammography (CESM) Early Quantitative Evaluation of Tumoral Response and Pathologic Complete Response Prediction for Localized Breast Cancer Treated by Neoadjuvant Chemotherapy (CERePred)

Breast Cancer

France
Wuhan Union Hospital, China

Not yet recruiting

Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy

Non-small Cell Lung Cancer | Pathological Complete Response | Neoadjuvant Chemoimmunotherapy | Deep Learning Model
Henan Cancer Hospital

Not yet recruiting

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Breast Cancer | HER2-positive Breast Cancer

China
Beckman Coulter, Inc.
Peking Union Medical College Hospital; West China Hospital; Second Affiliated...

Recruiting

Clinical Trial to Evaluate MDW for Early Detection of Sepsis

Sepsis

China
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic Syndrome (PROMETA)

Breast Cancer | Metabolic Syndrome

Italy
Jiangxi Provincial Cancer Hospital

Recruiting

The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC

Nasopharyngeal Carcinoma | Tumor Microenvironment | Pathologic Complete Response

China
Providence Health & Services

Recruiting

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Primary Central Nervous System Lymphoma

United States
University of Oklahoma

Not yet recruiting

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Androgen Deprivation Therapy | Locally Advanced Prostate Cancer

United States
Brett A Faine
University of California, Los Angeles

Not yet recruiting

Patient-Directed Antimicrobial Duration in Acute Uncomplicated Pyelonephritis

Pyelonephritis Acute
Erasmus Medical Center

Recruiting

Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response (NIVOPTIMIZE)

Melanoma

Netherlands
University Medical Center Groningen
Centre Hospitalier Universitaire de Nice; LungenClinic Grosshansdorf

Recruiting

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC (MRD-LUNG)

Lung Cancer Stage III

France, Germany, Netherlands
Assiut University

Not yet recruiting

Blood Indices of Systemic Inflammation in Critically Ill Patients With Abdominal Sepsis

Critically Ill | Abdominal Sepsis

Egypt
Maastricht Radiation Oncology
Varian Medical Systems

Not yet recruiting

Feasibility of the Maastro Applicator in Rectal Cancer

Quality of Life | Feasibility | Rectal Cancer | Toxicity | Radiation Toxicity | Brachytherapy | Radiation Proctitis | Complete Response
SciClone Pharmaceuticals

Not yet recruiting

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.

Neuroblastoma
University Institute of Maia
Centro Hospitalar de Vila Nova de Gaia/Espinho; Aveiro University; Associacao... and other collaborators

Recruiting

Improving Response to Chemotherapy by Adding Physical Exercise in the Neoadjuvant Setting of Breast Cancer Patients (KEYMOVE)

Breast Cancer

Portugal
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Omission of ALND in Breast Cancer Patients With Axillary pCR

Breast Cancer | Pathological Complete Response | Axillary Lymph Node Dissection | Neoadjuvant Systemic Therapy | Axillary Lymph

China
Shanghai Pulmonary Hospital, Shanghai, China
Zunyi Medical College; Ningbo HwaMei Hospital, Zhejiang, China; The First Affiliated...

Recruiting

Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Neoadjuvant Chemoimmunotherapy | Complete Pathological Response

China
Henan Cancer Hospital

Recruiting

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Breast Cancer | HER2-positive Breast Cancer

China
Fifth Affiliated Hospital, Sun Yat-Sen University

Recruiting

The Efficacy and Safety of De-escalated Postoperative Radiotherapy in Locally Advanced HNSCC With pCR/MPR

Head and Neck Squamous Cell Carcinoma

China
The First Hospital of Jilin University

Recruiting

An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCL

PTCL Patients Who Achieved Complete Response From Frontline Treatment

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma

United States, Puerto Rico
Kezar Life Sciences, Inc.

Recruiting

A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

Lupus Nephritis

United States, Korea, Republic of, Australia, Malaysia, Taiwan, South Africa, China, Singapore, United Kingdom, Puerto Rico, Croatia, India, Greece, Spain, Brazil, Philippines, Guatemala, Argentina, Portugal, Colombia
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Federico II University; Humanitas Clinical and Research Center; Istituto Oncologico... and other collaborators

Recruiting

Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial (BREAKFAST-2)

Breast Cancer | Triple Negative Breast Cancer | Fasting | Dietary Exposure

Italy
Samara State Medical University

Recruiting

Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML

Endothelial Dysfunction | Cardiotoxicity | Acute Myeloid Leukemia, Adult

Russian Federation
Centre Leon Berard

Recruiting

Multiparametric Quantitative MRI and Response to Neoadjuvant Radiotherapy for Soft-tissue Sarcoma (SarQuantIRM)

Soft Tissue Sarcoma | Resectable Soft Tissue Sarcoma | Adult Soft Tissue Sarcoma

France
Ruijin Hospital
The First Affiliated Hospital of Anhui Medical University; The First Affiliated... and other collaborators

Recruiting

Genotype-guided Treatment in Newly Diagnosed PTCL (THEORY)

Peripheral T Cell Lymphoma

China
AstraZeneca
SWOG Clinical Trials Partnerships; Daiichi Sankyo

Recruiting

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Breast Cancer

United States, China, Denmark, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Belgium, Spain, Japan, France, Taiwan, Greece, Brazil, Sweden, Puerto Rico
University of Florida
National Institute of General Medical Sciences (NIGMS)

Recruiting

Pathological Myeloid Activation After Sepsis and Trauma

Sepsis | Trauma Injury | Immunosuppression | Chronic Critical Illness

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation (JANUS)

Stage III Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Locally Advanced Rectal Carcinoma

United States, Puerto Rico
Guangdong Provincial People's Hospital

Recruiting

Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients (PICCRT)

Esophageal Squamous Cell Carcinoma | Immunotherapy | Patient-reported Outcomes

China
VA Office of Research and Development
VA Palo Alto Health Care System; VA Puget Sound Health Care System; Michael E... and other collaborators

Not yet recruiting

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Carcinoma

United States
Renmin Hospital of Wuhan University

Recruiting

Short-course Radiotherapy Combined With Neoadjuvant Chemotherapy and PD-1 Inhibitor in the Treatment of Locally Advanced Gastric Adenocarcinoma

Disorder in Complete Remission in Response to Treatment

China
Pfizer

Recruiting

Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

Migraine

Spain, Canada, United States, Poland, Belgium, Finland, Denmark, Austria, Italy, Sweden, Germany, Australia, United Kingdom, Mexico

Search clinical trials for: complete cytogenetic response

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations